NGEN Earnings Date: Nov 12, 2026 (Estimated) — NervGen Pharma Corp. Common stock

NASDAQ · Healthcare · Biotechnology

Updated Oct 30, 2026

Price $1.39

Market Cap $111.7M

P/E -2.4

52W Range $1.35 – $6.30

Next Earnings Nov 12, 2026 (est.)

When is NGEN's next earnings date?

NervGen Pharma Corp. Common stock (NGEN) is expected to report earnings on Thursday, November 12, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.10.

How did NGEN do in its last earnings report?

In its most recent report on Aug 13, 2026 (Q2 2026), NervGen Pharma Corp. Common stock posted EPS of -$0.27 versus the -$0.06 estimate, a miss of 345.7%. Revenue was $0 against a $4,500 estimate. The stock's 1-day post-earnings move was +0.0%.

How much does NGEN stock move after earnings?

NGEN beat EPS estimates in 0 of its last 1 reported quarter.

About NervGen Pharma Corp. Common stock

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.